Somatostatin analogs may have antifibrotic properties in the lung. The aim of this study was to evaluate the expression of the five somatostatin receptors sst1 to sst5 in the normal and fibrotic mouse lung and the action of SOM230 (pasireotide), a new somatostatin analog with a long half life, in bleomycin-induced lung fibrosis and in human lung fibroblasts in vitro. After intratracheal injection of bleomycin, C57Bl6 male mice received one daily sub-cutaneous injection of SOM230 or saline. The lungs were evaluated on day 3, 7 and 14 after bleomycin.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease which carries a poor prognosis.
To date, no treatment has been demonstrated to prevent the evolution of fibrosis in IPF patients and new therapeutic opportunities are needed. While the pathophysiology of pulmonary fibrosis is poorly elucidated, it is characterised at the microscopic level by fibroblasts accumulation and extracellular matrix deposition in the lung, leading to alveolar wall thickening and loss of elasticity. Apart from chronic lung inflammation, which probably participates in the pathophysiology of the disease [1] , the recruitment, activation and proliferation of fibroblasts are now considered key features during the development of pulmonary fibrosis and therapeutic agents targeting fibroblasts are being evaluated in idiopathic pulmonary fibrosis [2] .
Somatostatin is an endogenous cyclic peptide initially identified as a regulator of Growth
Hormone secretion. Five somatostatin receptors, named sst1, sst2A, sst3, sst4 and sst5, have been described in humans, that equally bind somatostatin. Although the relative expression and the localisation of these receptors vary within organs, their expression in the lung has been poorly studied. In a previous study, our group has shown that human lung fibroblasts, from normal and fibrotic lung, bound radiolabeled somatostatin in vitro [3] . We also evidenced an increased uptake of radiolabeled octreotide (a somatostatin agonist) in the lung in patients with IPF when compared to control patients [3] . Most importantly, the octreotide uptake correlated with the severity of lung fibrosis [3] . Altogether, these data suggested that somatostatin receptors were increased in IPF lungs.
Somatostatin and its pharmacological analogs display anti-fibrotic activities in vitro and in vivo in different experimental settings [4] . The pathways involved in this antifibrotic effect are not completely elucidated but inhibition of transforming growth factor-β1 (TGF-β1) production [5, 6] as well as a degree of anti-inflammatory actions [7] may contribute to the group.bmj.com on December 19, 2017 -Published by http://thorax.bmj.com/ Downloaded from 3 protective effect. However, the antifibrotic effect of somatostatin and its analogs has never been evaluated in the lung. SOM230 (pasireotide) is a new somatostatin analog that binds four out of the five sst receptors (sst1, sst2A, sst3 and sst5) and has a long half-life which makes it suitable for a therapeutic use [8] . In this study we evaluated the antifibrotic effect of SOM230 in a bleomycin-induced lung fibrosis model in mice. We quantified the expression and localization of somatostatin receptors (sst1 to sst5) in the normal and fibrotic lung, and we evaluated whether SOM230 modulated the TGF-β and CTGF profibrogenic pathways. Furthermore, we characterized the effect of SOM230 on human lung fibroblasts in vitro.
MATERIAL AND METHODS

Bleomycin animal model
Male C57BL/6J mice (R. Janvier, Le Genest St Isle, France), aged 6-7 weeks, were kept in accordance with INSERM rules. On day 0, the mice were administered 80 µg bleomycin hydrochloride (Bleomycine Bellon, Aventis, Paris, France) intratracheally, and were randomly assigned to receive either SOM230, 25 µg/kg/day (bleo+SOM mice) or 2.5 µg/kg/day, or an equal volume of saline (bleo+vehicle mice). SOM230 was diluted in 100 µl saline and sub-cutaneously administered daily beginning immediately after bleomycin injection. Mortality was assessed daily over a 14 days-period. For further analysis, animals were sacrificed on day 3, 7 or 14 after bleomycin admnistration.
To evaluate the effect of late treatment, SOM230 (25 µg/kg/day) or vehicle was given from day 5 to day 13. The animals were sacrified at day 14. Naïve mice were used as controls. The doses of SOM230 used in this study were similar to those used in previous experiments [9] .
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In further experiments, controls animals received SOM230 (25µg/kg/day) or vehicle for 3, 7 or 14 days, and were sacrificed at each time point (N=6 per time).
Tissue sampling, lung histology, TGF-β1 assay and mRNA analysis At specified time points, the animals were euthanised and the lungs were freed of blood by perfusion. Bronchoalveolar lavage (BAL) was performed with 1ml of saline. Total and differential cell counts were estimated. BAL supernatant was stored at -80°C until TGF-β1 assay.
Total TGF-β1 was measured after acidification of the samples according to the manufacturer instructions (Quantikine®, R&D System Europe, Lille, France).
Semi-quantitative assessment of lung injury used the grading system described by Inoshima and colleagues [10] .
Lung collagen was quantified in snap-frozen right lungs with the Sircol collagen assay (Biocolor Ltd, Newtownabbey, UK).
RNA extraction and real time quantitative PCR were performed on left mouse lungs using standard protocols (see on line supplement). The expression of the gene of interest was expressed as a ratio to the Ribosomal Protein L13 (RPL13) gene as previously described [11] .
Immunohistochemical detection of somatostatin receptors
The sst2 receptor was detected by immunohistochemistry on mice samples with a rabbit polyclonal anti-mice sst2A antibody (ref SS-800, Biotrend, Cologne, Germany) (1/400 dilution). Immunodetection was performed on frozen human lung tissue samples (from 3 controls and 5 patients with IPF, diagnosed according to the ATS/ERS consensus criteria
[12]-the origin of lung samples has been previously described [11] ) and cultured human 
RESULTS
Somatostatin receptors are present in the lung and their expression is modulated after bleomycin instillation
In the naive mice, all somatostatin receptors (sst1 to sst5) mRNA were detected in the lung, with very low levels of expression of sst5 (figure 1). After bleomycin instillation, the expression of sst2A and sst5 mRNA was strongly increased, with a maximum at day 7, whereas the expression of sst1 and sst4 mRNA was decreased (figure 1).
Treatment with SOM230 of bleomycin-injected mice temporarily increased the expression of 
Treatment with SOM230 attenuated bleomycin-induced pulmonary fibrosis.
We analyzed the histological changes in the lung of surviving mice at day 14 following bleomycin instillation in bleo+SOM mice (25 µg/kg/day, n=11; 2.5 µg/kg/day, n=7) compared to bleo+vehicle mice. As shown in figure 4, the treatment with SOM230 25 µg/kg/day improved the pathological score at day 14, when compared to bleo+vehicle mice (P=0.03) whereas the lower dose (2.5 µg/kg/day) had no effect. In view of these favorable results, the 25 µg/kg/day dose of SOM230 was used in further experiments.
SOM230 reduced lung collagen concentration
Treatment with SOM230 reduced lung collagen content on day 14 (112 µg/lung In the bleo+vehicle mice, alpha-2 collagen-1 (COL1A2) mRNA lung content was increased at day 3 after bleomycin instillation, peaked at day 7, and then decreased by day 14 (figure 4). SOM230 treatment strongly inhibited the peak of COL1A2 mRNA expression in the lung at day 7 (COL1A2/RPL13 mRNA ratio = 2.6 in the bleo+SOM mice versus 23 in the bleo+vehicle mice, P=0.01). SOM230 had no effect on COL1A2 mRNA contents at other time points. These results show that the reduction of collagen content at day 14 was preceeded by a reduction in COL1A2 mRNA at day 7.
Treatment with SOM 230 reduced lung inflammation and inhibited the increase of TGF-β1 and CTGF
Treatment with SOM230 reduced the alveolar inflammatory cells influx at early times as assessed by the reduction of total BAL cellularity, BAL macrophages and BAL lymphocytes counts on day 3 (Table 1) . On day 7 and day 14, BAL cellularity was similar in bleo+SOM and bleo+vehicle mice (data not shown). Furthermore, SOM230 promoted the expression of hepatocyte growth factor (HGF) and keratinocyte growth factor (KGF) (two antifibrotic mediators) after bleomycin, and reduced lung CTGF mRNA content by 30% when given to naive mice (see on line data supplement).
Effect of late treatment with SOM230
In a further set of experiments, we assessed the protective effect of SOM230 given daily later after bleomycin instillation. Mice were started with SOM230 (25 µg/kg/day) from day 5 after bleomycin instillation until day 13.
In these experiments, the pathological score (score > In vitro, fibroblasts cultured from normal lung and fibrotic lung strongly expressed the sst2 receptor as assessed by immunohistochemistry ( Figure 7 ). The intensity of labeling was similar in the two groups. Emerging data suggest that somatostatin may have interesting antifibrotic properties, both in vitro and in vivo, which we have confirmed in this study using an in vivo model of lung fibrosis.
DISCUSSION
First, we demonstrated the expression of somatostatin receptors in the lung. All sst receptors mRNA were detected in mice lung, although the sst5 receptor was expressed at a very low level. Interestingly, sst receptors mRNA expression appeared to be differentially modulated following bleomycin-induced lung fibrosis: the expression of sst2A and sst5 mRNA was strongly increased, the expression of sst1 and sst4 mRNA was decreased, whereas the expression of sst3 mRNA remained unchanged. The increased expression of the sst2 receptor is of paramount importance since the sst2 receptor is thought to play a prominent role in the biological effects of somatostatin analogs [13] . Increased mRNA expression was associated with an increase of the sst2 positive cells on immunohistochemistry. The later results are reminiscent of our previous report of increased uptake of radiolabeled octreotide in patients with IPF [3] .
Interestingly, both inflammatory cells and resident lung cells expressed the sst2 receptor in mice and human samples as detected by immunohistochemistry. In the bleomycin mouse model, the increased expression of sst2 was due, at least in part, to an influx of inflammatory cells, particularly monocytes and macrophages. The expression of sst2 has been shown to be upregulated in activated monocytes [14] . Our results support data indicating that somatostatin analogs exert anti-inflammatory effects on lymphocytes, macrophages and neutrophils [15] [16] [17] [18] [19] [20] . Interestingly, SOM230 reduced the alveolar inflammatory cells influx on day 3, demonstrating an anti-inflammatory action of the compound in this model.
Although somatostatin and its analogs have shown interesting antifibrotic properties in a number of animal models, they have never been tested previously in a model of pulmonary fibrosis. Octreotide is the most extensively studied molecule in this field. In rats, octreotide inhibits the development of liver fibrosis induced by extrahepatic biliary obstruction or carbon tetrachlorure poisoning [21, 22] , inhibits esophageal or digestive fibrosis induced by radiation [6, 23] , and decreases the accumulation of connective tissue in a murine model of hepatic schistosomiasis [24] . Somatostatin and its analogs develop their antifibrotic action through different mechanisms. Somatostatin has been shown to promote fibroblasts apoptosis in vitro through its sst2 receptor [25] whereas octreotide inhibits the proliferation of skin and orbital fibroblasts [26, 27] . In vitro, somatostatin modulates fibroblasts proliferation through the activation of the ERK and MAPkinase pathways [4] . We show in this study that SOM230 inhibits human lung fibroblasts proliferation in vitro. Some data suggest that somatostatin analogs may act through an inhibition of TGF-β production [5, 23, 28] although TGF-β inhibition was not apparent in all models studied [6] . TGF-β is the prototypical profibrotic mediator in the lung. TGF-β has been shown to increase the expression of the sst2 receptor in mice, through a Smad4-dependent pathway [29] . Broad expression of sst receptors in the lung indicates that beside the fibroblasts, SOM230 may have many cellular targets, both on resident cells and inflammatory cells, all possibly contributing to its protective action.
Interestingly, SOM230 seems to downregulate macrophages and lymphocytes lung infiltration on day 3, but not neutrophils (table 1) . This phenomenon could be due to a direct effect of SOM230 on leukocytes survival. Indeed, somatostatin inhibits proliferation and promotes apoptosis in lymphocytes [30] and reduces macrophages viability [31] , but such an effect has not been reported with neutrophils. SOM230 could also differentially modulate the 12 expression of chemoattractants and adhesion molecules. We did not specifically adress this point. In one study, somatostatin did not modify neutrophil migration in vitro in response to different stimuli [32] .
The protective effect of SOM230 in our study is consistently associated with a decrease of TGF-β1 expression, observed both when SOM230 was given from day 0 to day 14, or when given later, from day 5 to day 14. Reduced expression of TGF-ß1 may contribute to the strong inhibition of lung CTGF expression that we observed on day 7 since CTGF expression is selectively induced by TGF-β1 [33] . In vitro, octreotide, a somatostatin analog, inhibits the expression of TGF-β and CTGF mRNA by hepatic stellate cells [34] . Whether somatostatin analogs modulate directly CTGF expression is unknown but may be supported by our observation that SOM230 reduced lung CTGF mRNA in control mice treated with SOM230.
Interestingly, our results suggest that SOM230 could exert its antifibrotic properties through the increased expression of antifibrotic mediators, such as HGF and KGF (see on line supplement). HGF and KGF are produced mainly by fibroblasts [35] . Our group has previously shown that human lung fibroblasts cultured from the IPF lung have a reduced capacity to secrete HGF and KGF [36, 37] and to activate proHGF [11] . Reduced expression of TGF-β1 by SOM230 explain the increase in HGF and KGF expression since TGF-β1 is a known inhibitor of HGF and KGF expression [35] .
We observed that endothelial cells expressed the sst2 receptor in the lung, both in mice and in human IPF lung. This result is in agreement with previously reported evidence of the effect of SOM230 in reducing endothelial cell proliferation in vitro [38] and its action as an anti-angiogenic drug [39] . This is particularly interesting since increased vascularity is a hallmark of IPF [40] and reduction of aberrant angiogenesis reduces the development of group.bmj.com on December 19, 2017 -Published by http://thorax.bmj.com/ Downloaded from bleomycin-induced pulmonary fibrosis [41] . These findings could further explain the antifibrotic effect of SOM230.
We also have shown that SOM230 inhibits collagen-1 mRNA expression by human lung fibroblasts stimulated in vitro with TGF-β1 (see on line data supplement). Interestingly, the maximal inhibition was obtained with low concentrations of SOM230 (10 -10 M), that are likely to be obtained in vivo. Somatostatin has been previously shown to directly inhibit the expression of collagen and alpha-smooth muscle actin in hepatic stellate cells [42] . In that study, the inhibition of collagen expression was also obtained only with low concentrations of somatostatin (10 -9 M); the authors attributed this effect to desensitization of somatostatin receptors with higher doses [42] . Alpha-2 collagen-1 (COL1A2) mRNA expression was assessed by quantitative real time PCR and expressed as the ratio to RPL13 mRNA content in the lung of naive mice (controls) and at day 3, day 7 and day 14 after bleomycin instillation (panel E). In bleo+vehicle mice COL1A2
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SOM230 treatment inhibited the peak of COL1A2 mRNA expression at day 7. SOM230 had no effect at other time points (n=5 to 7 animals for each experimental condition). *P<0.05.
The centerline of the box denotes the median, the extremes of the box denote the interquartile range and the bars denote the highest and lowest values. Panel B: CTGF mRNA content was assessed by quantitative real time PCR and expressed as the ratio to RPL13 mRNA content in the lung of naive mice (controls) and at day 3, day 7 and day 14 after bleomycin instillation. In bleo+vehicle mice CTGF mRNA content was increased at day 3 with a maximum at day 7. SOM230 treatment inhibited the peak of CTGF mRNA expression at day 7. SOM230 had no effect on CTGF mRNA content at other time points.
The centerline of the box denotes the median, the extremes of the box denote the interquartile range and the bars denote the highest and lowest values. (n=5 to 9 animals for each experimental condition). * P<0.05 
